Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;14(9):565-574.
doi: 10.1038/nrurol.2017.82. Epub 2017 Jul 4.

Landmarks in the treatment of muscle-invasive bladder cancer

Niyati Lobo  1 , Chloe Mount  1 , Kawa Omar  1 , Rajesh Nair  1 , Ramesh Thurairaja  1 , Muhammad Shamim Khan  1
Affiliations
Review

Landmarks in the treatment of muscle-invasive bladder cancer

Niyati Lobo et al. Nat Rev Urol. 2017 Sep.

Abstract

Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first reported cystectomy in 1887 to include pelvic lymph node dissection and the creation of increasingly sophisticated urinary diversions, such as neobladders and pouches, which enable patients to maintain continence. Pioneering work in the 1970s established the therapeutic activity of cisplatin in patients with bladder cancer and resulted in the introduction of cisplatin-based neoadjuvant chemotherapy, which led to the first improvement in survival outcomes in decades. Other notable advances include the development of bladder-sparing protocols, which combine surgery, chemotherapy, and radiotherapy. Molecular profiling of bladder cancer has helped to enhance our understanding of tumour biology and identify several therapeutic targets, such as programmed death (PD-1) and its ligand programmed cell death ligand 1 (PD-L1). Over the past 3 years, immune checkpoint inhibitors targeting the PD-1-PD-L1 axis have demonstrated the ability to achieve durable objective responses in trials of patients with metastatic disease. If the current momentum continues, immunotherapy is poised to change the landscape of muscle-invasive bladder cancer treatment, promising improved survival outcomes for patients with this disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer. 1956 May-Jun;9(3):551-8 - PubMed
    1. Int J Radiat Oncol Biol Phys. 1981 May;7(5):569-73 - PubMed
    1. Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):261-6 - PubMed
    1. Eur Urol. 2015 Mar;67(3):402-22 - PubMed
    1. Anticancer Res. 1998 May-Jun;18(3B):1931-4 - PubMed

MeSH terms